glp-1 etf Inside the Boom: Picks for the Obesity Drug Market HRTS is the World's First

Sitagliptin was approved in 2006, but in contrast to the GLP-1 agonists, DPP4 inhibitors have little or no effect on body weight

Ozempic is not FDA-approved for weight loss, so Aetna typically wont cover it for that purpose

Data presented in this article are from a survey fielded to the full roster of both active and inactive panelists ages 18 and older ( N = 16,029) between May 19, 2025, and June 13, 2025

Biomed Pharmacother 181: 117668, 2024

The hyperglycemic group had significantly higher miR-27a expression and lower PPAR expression compared to the control group

Impact on AMD A 2025 retrospective published in JAMA Ophthalmology looked at the incidence of developing wet age-related macular degeneration (AMD) three years after initiation of treatment with GLP-1 drugs